Oral News and Research

RSS

IDSA guidelines describe best methods for diagnosis of prosthetic joint infections

Of the one million people each year who get hips and knees replaced, as many as 20,000 will get an infection in the new joint, a number that is expected to skyrocket in the next 20 years. Multispecialty physician teams need to work together to reduce disability, death and costs associated with the ever-growing number of these prosthetic joint infections, note the first guidelines on the topic being released by the Infectious Diseases Society of America (IDSA).

9 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Elderly cope better with oral cancer

Older individuals with oral squamous cell carcinoma report better health-related quality of life at one year after curative surgical treatment than do their younger counterparts, indicate UK study results.

6 Dec 2012

Less is more when it comes to antibiotics for UTI in men

Research suggests that standard antibiotic prescribing for urinary tract infections in male patients may need to be reviewed, as currently recommended 7–14-day courses appear to be no more effective than shorter ones, and may increase the risk for antimicrobial resistant or Clostridium difficile infection.

6 Dec 2012

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR).

6 Dec 2012

Supreme Court hears arguments in hospitals' Medicare claims lawsuit

A majority of Supreme Court justices on Tuesday sounded skeptical of a suit brought by hospitals to reopen Medicare claims as much as 25 years old because of calculations that were found to have underpaid them.

6 Dec 2012

University of Florida initiates enrollment in SPI-1005 Phase II trial for sensorineural hearing loss

The University of Florida (UF) has started enrolling subjects in a new study testing the oral drug developed by Sound Pharmaceuticals, Inc. (SPI-1005) to prevent hearing loss caused by loud music. Loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS).

6 Dec 2012

Ponatinib offers new hope in drug-resistant leukemia

An investigational tyrosine kinase inhibitor, ponatinib, has shown high levels of activity in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

5 Dec 2012

National Radiation Oncology Registry program for quality assessment and improvement

The National Radiation Oncology Registry (NROR) pilot program will serve as the basis for the creation of a nationwide electronic registry to capture reliable, population-based information on radiation treatment delivery and health outcomes and will be supported by an innovative information technology (IT) infrastructure that will maximize efficiency through the automated collection and electronic transfer of data, according to research presented at the American Society for Clinical Oncology (ASCO) Quality Care Symposium.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Regular, moderate coffee consumption may help prevent type 2 diabetes

Drinking three to four cups of coffee per day may help to prevent type 2 diabetes according to research highlighted in a session report published by the Institute for Scientific Information on Coffee (ISIC), a not-for-profit organisation devoted to the study and disclosure of science related to coffee and health.

5 Dec 2012

Sputum color guides antibiotic treatment in COPD

Withholding antibiotic treatment from hospitalized chronic obstructive lung disease patients with nonpurulent sputum does not negatively affect outcomes, a pilot study shows.

4 Dec 2012

Mouthwash may reduce bacteremia after wisdom tooth extraction

Use of a povidone iodine- or chlorhexidine-based mouthwash immediately before third molar extraction reduces bacteria levels in patients' blood after the procedure, Turkish study findings reveal.

4 Dec 2012

Combined oral contraceptives increase risk of blood clots in women with PCOS

Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal).

4 Dec 2012

Merck commences MK-8931 Phase II/III trial in Alzheimer's

Merck, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

3 Dec 2012

Mistletoe extract plays a vital role in treating colon cancer

Mistletoe has become an important symbol of Christmas but it also has the potential to play a vital role as an alternative therapy for sufferers of colon cancer.

30 Nov 2012

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Home Access Health urges individuals at risk for HIV infection to get tested

Home Access Health Corporation, America's leading provider of at-home HIV tests, today recognized World Aids Day Saturday by urging individuals at risk for HIV infection to get tested.

30 Nov 2012